System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 37 citations

PubMed: 37111341 DOI: 10.3390/ph16040584

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease.

Pharmaceuticals (Basel) 16(4)

Authors: Janis Kay Shute

Affiliations

  • School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth PO1 2UP, UK.

Abstract

Unfractionated heparin has multiple pharmacological activities beyond anticoagulation. These anti-inflammatory, anti-microbial, and mucoactive activities are shared in part by low molecular weight and non-anticoagulant heparin derivatives. Anti-inflammatory activities include inhibition of chemokine activity and cytokine synthesis, inhibitory effects on the mechanisms of adhesion and diapedesis involved in neutrophil recruitment, inhibition of heparanase activity, inhibition of the proteases of the coagulation and complement cascades, inhibition of neutrophil elastase activity, neutralisation of toxic basic histones, and inhibition of HMGB1 activity. This review considers the potential for heparin and its derivatives to treat inflammatory lung disease, including COVID-19, ALI, ARDS, cystic fibrosis, asthma, and COPD via the inhaled route.

MeSH

Anticoagulants, Lung, Neutrophils, Heparin, Cystic Fibrosis, Therapeutics, Asthma, Lung Diseases, Heparin, Low-Molecular-Weight

Cited by